Caplin Point Laboratories Limited

CAPLIPOINT

INE475E01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:50 31/05/2024 BST			5-day change	1st Jan Change
1,290 ^INR	-0.12%		-0.98%	-4.91%

05-24	Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	MT
05-16	Caplin Point Laboratories to Seek Acquisitions	CI

Caplin Point Laboratories Limited Announces Cessation of K C John's Independent Directorship

September 05, 2022 at 08:31 am

Caplin Point Laboratories Limited announced the cessation of Dr. K C John's Independent Directorship on the Board of the Company with effect from August 25, 2022, in line with the terms approved by the Shareholders.

Latest news about Caplin Point Laboratories Limited

Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	05-24	MT
Caplin Point Laboratories to Seek Acquisitions	05-16	CI
Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024	05-16
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024	05-16	CI
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-16	CI
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India	05-06	MT
Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry	05-06	CI
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	04-16	MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	03-28	MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	03-28	CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	03-27	MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	03-27	CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	02-09
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	01-08	MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	01-08	MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	12-14	CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023	11-09
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	22/09/23	CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	04/09/23	MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023	08/08/23
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/08/23	CI
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	07/08/23	CI
Caplin Point Laboratories to Incorporate Step-Down Subsidiary in US	03/08/23	MT

Chart Caplin Point Laboratories Limited

Duration

Period

More charts

Company Profile

Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Companyâs subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Caplin Point Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,290 INR

Average target price

1,579 INR

Spread / Average Target

+22.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CAPLIN POINT LABORATORIES LIMITED	-4.91%	1.17B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.35%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.90%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals